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Introduction
Muckle-Wells syndrome (MWS) is caused by muta-
tions in the NLRP3-gene encoding cryopyrin, leading
to overproduction of IL-1b and other NLRP3 inflam-
masome products. Myeloid-derived suppressor cells
(MDSCs) represent a novel innate immune cell subset,
are generated in tumor, infective, and proinflammatory
microenvironments and are capable of suppressing
T cell responses. Consequently, MDSCs are considered
a key intermediary in balancing innate and adaptive
immune responses, particularly under chronic disease
conditions.
Objectives
We hypothesized that NLRP3 inflammasome-dependent
factors induce the generation of MDSCs in MWS.
Methods
We studied granulocytic MDSC numbers in 25 MWS
patients under anti-IL-1 therapy with canakinumab
and 20 healthy controls. After Ficoll density gradient
sedimentation, granulocytic MDSCs were character-
ized as CD33highCD66bhighIL-4RainterHLA-DRlow neu-
trophilic cells in the PBMC fraction, according to
previously established human MDSC analysis methods.
The functionality of MACS-isolated MDSCs was
assessed using polyclonal T cell proliferation and cyto-
kine/chemokine secretion tests. Physician ’s global
assessment of disease activity, CRP, ESR, and T helper
cell subsets were determined at the same time points
and correlated with MDSC levels. Serum samples of
22 MWS patients and 5 healthy controls were exam-
ined by multiplex technique for possible MDSC indu-
cing factors.
Results
MWS patients under anti-IL-1 therapy displayed signifi-
cantly elevated MDSC numbers (mean 1.65 ± 0.33%;
range 0.16 - 5.17%) compared to healthy controls (mean
0.45 ± 0.05%; range 0.12 - 1.04%; p = 0.0025), although
clinical MWS-disease activity was generally low at time
of examination. MDSCs were functionally competent, as
they suppressed polyclonal T cell proliferation, Th1,
Th2, and Th17 responses. MDSCs correlated directly
with Treg/Th17 and Treg/Th1 ratios indicating an influ-
ence on T helper cell subsets. Multiplex assays revealed
the established MDSC-inducing growth factors GM-CSF
and VEGF elevated in MWS sera even under anti-IL-1
therapy with canakinumab.
Conclusion
MWS patients under anti-IL-1 therapy display significantly
elevated numbers of granulocytic MDSCs. Increased
MDSCs in MWS might represent a novel autologous anti-
inflammatory mechanism in autoinflammatory conditions
and may serve as a future therapeutic target.
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